The global morbidity gap, meaning those living in poor health, has been increasing since 1990 and may continue based on trends through 2023.

Glucagon-like peptide-1 receptor agonists are associated with increased gastrointestinal adverse events and no symptom relief ...

Updated 2025-2026 formulations of mRNA-1283 and BNT162b2 protect older adults against severe COVID-19 outcomes and medically attended illness.

Perampanel offers meaningful seizure control and an acceptable safety profile for patients with brain tumor-related epilepsy, a new review shows.

The association between elevated interferon α and Sjögren disease sheds new light on immune pathways and disease.

An outside advisory panel to the FDA is pushing for the production and sale of a few previously banned peptide treatments.

Expanded genetic testing for amyotrophic lateral sclerosis may increase the demand for longitudinal surveillance of asymptomatic gene carriers.

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

Fecal microbiota transplantation may offer short-term improvements in motor function and constipation severity for adults with Parkinson disease.

Polyendocrine metabolic ovarian syndrome is associated with a higher incidence of atherosclerotic cardiovascular disease events.

Unfavorable sleep profiles and weaker rest-activity rhythms are associated with a higher prevalence of overactive bladder.

The Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593 for the treatment of narcolepsy. Narcolepsy type 1 is a rare neurological condition caused ...